Posts

IB Net Payout Yields Model

Bloom Energy: Not Pricing In Capacity Upside

Image
Update - Nov. 5, 2026 Wild to see  BE  down 15% today after the good news from CA and the analyst upgrade. If anything, Bloom Energy will be in more demand going forward. Note, the potential 1 GW deal in CA alone is nearly equal to 2026 sales. -Bloom Energy popped 8.9% in Tuesday's trading after Barclays upgraded the stock and the company unveiled a potential large-scale power partnership with California Resources Corp. to evaluate the potential development of at least 1 GW of fuel cell power generation paired with carbon capture and storage in the state. -Barclays upgraded Bloom (BE) to Overweight from Equal Weight with a $289 price target, saying demand appears to be inflecting more sharply than previously expected, as customer deposits increased from $78M in year-end 2025 to $661M in Q3 2026, including a ~$300M sequential increase in Q3 alone. Original article posted on Oct. 24  Bloom Energy delivered blockbuster Q3 '26 results, guiding up for Q4 and projecting robust ...

Nu Holdings: Buy Regardless Of The Brazilian Election Results

Image
Update - Oct. 27, 2026  Lulu winning the Brazilian election could present a good dip buying opportunity. Sounds like the election was pure chaos, so be careful rushing in to Nu. The stock appears to have hit a double bottom around $12.  -With 100% of the vote counted, Brazil’s electoral court announced that the soon to be 81-year-old Lula had a lead of nearly 4.4 million votes - 51.8% of the total vote - over opponent Flávio Bolsonaro. The announcement capped an evening of chaos at polling places across Brazil, following a last-minute decision to extend voting by two hours. That decision by a Supreme Court justice may trigger legal action by Bolsonaro. Original article posted on Oct. 14 Nu Holdings Ltd. remains maintains impressive growth, strong financials, and expansion into the U.S. market is a major catalyst. Recent Brazilian election results provide potential pro-business tailwinds, but policy implementation remains uncertain. NU trades at roughly 15x 2027 EPS targets, wi...

Netskope: Still An Overlooked AI Cyber Play

Image
Update - Oct. 22, 2026  Amazing to see Netskope run to $22 when the stock didn't want the stock at $8 post-IPO. The stock isn't even overly expensive yet at 8x '27 sales when Cloudflare (NET) trades at nearly 30x sales.  Original article posted on Sept. 5 Netskope delivered robust 29% revenue growth and strong ARR momentum yet remains undervalued versus peers. NTSK's unified SASE platform is highly rated, supporting enterprise AI adoption while maintaining 77% gross margins and positive free cash flow guidance. The AI network and security play reported net ARR grew 27% YoY, while net new ARR reached $54 million, up about 10% YoY. The stock trades at just 6x forward sales, offering faster organic growth than a major peer and presenting a compelling buy on dips. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios.  Learn More » Netskope, Inc.   ( NTSK )  has generally been an overlook...

Rocket Lab: Not Priced For Launch Delays

Image
Update - Oct. 15, 2026 Neutron delay doesn't alter the business model, but an investor should be less willing to pay such a premium valuation for the stock. Rocket Lab still trades at over 25x '27 sales targets that will start slipping due to the Neutron launch slip into next year.  -Rocket Lab (RKLB) shares fell 7.3% in extended trading Wednesday after the space launch company pushed the inaugural flight of its Neutron rocket into 2027, citing manufacturing problems involving a carbon-composite component of the vehicle's first-stage propellant tank. -The after-hours decline followed a 7.9% drop during regular trading Wednesday, adding to investor concerns about the development timeline for the larger rocket, which is central to Rocket Lab's (RKLB) efforts to expand its launch business. -Chief Executive Peter Beck disclosed the delay in a video update Wednesday, explaining that inspections uncovered tiny air pockets, known as voids, between layers of carbon fiber in the...

Verizon: Structural Problems Persist

Image
Update Oct. 8, 2026 The Starlink Mobile threat just got real. Verizon won't trade well with this news, but unfortunately most investors ignored this risk.  The stock is down to $43 in after hours.  Original article posted on Jul. 26 Verizon Communications remains structurally challenged, with no revenue growth and intensifying competition from Starlink and satellite communications. The wireless giant beat EPS estimates in Q2'26 via cost cuts, but missed revenue by nearly $1B and reported falling revenues, highlighting weak underlying demand. Management's aggressive buybacks and $12B annual dividend persist despite $165B in debt and limited capex flexibility, raising long-term sustainability concerns. The stock faces the same structural issues that have generated limited returns the last decade compared to over 300% in the S&P 500. Verizon Communications Inc.  ( VZ ) got a nice pop from quarterly earnings, but the business continues to face structural problems. The wir...

Cerebras: Forgotten AI Chip Stock

Image
Update - Oct. 8, 2026  Cerebras plummeted mid-day as confusing information surfaced regarding the revenue reported by key client OpenAI. Prior reports had suggested that ARR jumped to $70 billion despite sites like TickerTrends suggesting ARR was actually around $50 billion.  Now the market is viewing OpenAI revenue as slipping by $20 billion, but the reality is such a discrepancy in whether a site is reporting the gross ARR that includes payments to partners (Microsoft, AWS) or the new ARR. The financial picture of OpenAI isn't different.  Cerebras fell all the way to $161 on the news despite no impact to the $20+ billion deal with OpenAI. Apparently, the AI lab is already up to $55 billion in net ARR. The stock had fallen over $40 from the SemiAnalysis headlines to the OpenAI ARR drama, yet business is full-speed ahead.  Original article posed on Sept. 30 Cerebras Systems is undervalued amid confusing financials, despite massive AI market tailwinds and a $25B RPO, ...

Micron: Memory Boom Still Has Legs

  Micron Technology is positioned for multi-year growth, driven by strategic customer agreements and surging AI-related memory demand. MU's SCAs now cover 35% of revenues through 2030, with $150 billion in RPOs and potential revenues up to $433 billion, if pricing holds. Physical AI and autonomous vehicles are set to drive the next memory demand cycle, with humanoid robots requiring up to 20x the memory of premium smartphones. The stock trades at just 6x FY27 EPS estimates and is poised for aggressive buybacks; MU offers upside as elongated cycles and constrained supply support elevated earnings. Micron Technology, Inc.  ( MU ) remains a stock difficult to hold long term due to the normal cycle products in the memory space. Micron is silly cheap based on projected earnings, but the logical investor  has to fear a reversion to the mean with memory prices collapsing when the AI cycle ends. My  investment thesis  remains Bullish on the stock after holding the $1,05...

Bloom Energy: Don't Buy Just For S&P 500 Bonus (Rating Upgrade)

Image
Update - Sept. 24, 2026 Any dip on the Oracle Project Jupiter dip is just a buying opportunity. The demand for on-site power isn't slowing down and Oracle still has plans to deploy up to 3 GW of fuel cells with Bloom Energy. -Bloom Energy ( BE ) shares fall 5.4% pre-market Thursday after Oracle ( ORCL ) sent the developer of its Project Jupiter data center site a notice citing force majeure, Bloomberg reported; the project is designed to be powered by Bloom Energy fuel cells. -Oracle, down 4.5% pre-market, reportedly is seeking to protect itself ​from potential cost increases related ‌to the New Mexico project in New Mexico by sending the notice to developer ​Blue Owl. -Oracle is aiming ​to delay payments if ⁠Project Jupiter fails to come online in 2028 as planned, rather than exiting ​as the ​main tenant, ⁠according to the report. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios.  Learn More » ...

Rivian: Thank You, Demos!

Image
  Rivian Automotive is positioned for aggressive growth, as R2 production ramps and demo drives surge. Q3 demo drives are on pace to nearly double Q2, signaling strong demand and supporting a delivery ramp to over 20,000 vehicles. RIVN's 2026 delivery forecast is 65,000–70,000 vehicles, still only 30% of its Normal, IL, plant capacity, with further upside from the Georgia facility. With a $23B market cap and potential $31B+ sales target for current production plans, stars are aligning for RIVN's rapid revenue expansion, including autonomy and VW software deals. Rivian Automotive, Inc. ( RIVN ) has big expansion plans, but the company needs R2 sales to ramp dramatically over the prior versions to be successful. The biggest risk is demand drying up long before the  company reaches goals to 10x production in the next few years and the strong R2 demo drives is a very positive indication. My  investment thesis  is ultra Bullish on the EV manufacturer still trading near th...

Palo Alto Networks: Mismatched AI Cybersecurity Excitement

Image
Update - Sept. 2, 2026 Palo Alto Networks with the solid beat as expected. The stock just has nowhere to go at this valuation, leading to the 9% dip following earnings. The cybersecurity company forecast a FY27 EPS of only $4.175 for only around 9% growth while the stock still trades at 78.5x EPS targets. The numbers just don't support the big rally.  -FQ4 Non-GAAP EPS of $1.02 beats by $0.04. -Revenue of $3.41B (+34.3% Y/Y) beats by $60M. These FY27 guidance numbers appear very low. -Next-Generation Security ARR of $11.075 billion to $11.175 billion, representing year-over-year growth of 22% to 23%. -Remaining performance obligations of $25.2 billion to $25.4 billion, representing year-over-year growth of 19% to 20%.   Original article posted on Aug. 29 Palo Alto Networks trades near all-time highs, with the stock valuation far outpacing business fundamentals and organic growth trends. PANW's organic growth slowed to ~14% in the last quarter, while EPS growth is muted due to ...

USA Rare Earth: Progress Over Perfection

  USA Rare Earth is rapidly scaling a vertically integrated rare earths business, yet the market remains skeptical of its long-term profitability. The recent quarterly results weren't impressive, but the numbers aren't relevant; focus on operational milestones, customer pipeline, and magnet production ramp at Stillwater and future expansions. USAR's valuation appears compelling, targeting $1.85B adjusted EBITDA by 2030 and ~80% free cash flow conversion, with debt expected to be generally covered by 2030. The stock is cheap at about 3.5x adjusted EBITDA targets with dips down to the $15 range—great buying opportunities. USA Rare Earth, Inc. ( USAR ) is quickly building a rare earth powerhouse, but the stock market still isn't convinced of a profitable future. The company is early in the development process, leading to some confusion over financial  results. My  investment thesis  remains ultra bullish on the stock, especially back at the recent lows when the stock ma...

Joby Aviation: Held Back By Untimely Capital Raises

Image
Joby Aviation is deeply undervalued at $7, despite strong progress toward eVTOL certification and air taxi launch. The potential $750M ATM capital raise, linked to the $500M Resonant Sciences acquisition, pressures the stock but adds a $100M+ revenue defense unit. JOBY is on track for a $2B revenue target by 2030, with near-term catalysts including eIPP services in Dallas-Fort Worth and Dubai. Certification delays and ongoing capital raises remain key risks, but current weakness offers a compelling buying opportunity. Joby Aviation, Inc.  ( JOBY ) appears to have a bright future, but the company can't stop making untimely capital raises. The stock trades at multi-year lows despite the progress towards eVTOL certification and air taxi  launch. My  investment thesis  remains ultra Bullish on the stock trading around $7, but Joby Aviation is unlikely to rally as long as the company constantly raises capital regardless of the stock price. Read the full article on Seekin...

Firefly Aerospace: Riding The Space Race Higher

Image
  Firefly Aerospace Inc. trading at a discount to peers amid strong quarterly results and robust backlog growth. The Q2 backlog surged to a record $1.5 billion, supported by moon landing missions and Lockheed Martin launches, supporting a strong long-term growth trajectory. FLY's revenue guidance for 2026 remains $420–$450 million, with order timing causing quarterly volatility. The stock only trades at 4x 2028 sales targets, while rocket launch companies trade at multiples of this price. Firefly Aerospace Inc. ( FLY ) was an amazing gift on the dip back to support around $20. The space infrastructure company continues to pull large orders as Firefly expands manufacturing capabilities to ride the space race. My  investment thesis  remains ultra Bullish on FLY stock, which is trading at a discount to other rocket launch and space companies. Read the full article on Seeking Alpha. Disclosure: No position. mentioned. Please review the disclaimer page for more details

Moderna: Focus On Cancer Vaccines, Not Buyout

Image
Update - Aug. 19, 2026 MODERNA, MERCK  MRNA  CANCER VACCINE SUCCEEDS IN PHASE 3, stock up nearly 150% to $153 mid-day trading. The stock is now up nearly 500% from where our research highlighted the potential benefits of a cancer vaccine.  - MRNA  and  MRK  say their personalized mRNA cancer vaccine, intismeran, combined with Keytruda slowed melanoma recurrence and spread in a late-stage trial. -The study was stopped at its first interim analysis after positive results, though detailed efficacy data have not yet been released.   Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios.  Learn More » Original article posted on Oct. 31, 2025 Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on mRNA Covid vaccines boosting cancer surv...